nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—UGT2B7—Epirubicin—sarcoma	0.209	0.269	CbGbCtD
Dapagliflozin—CYP1A1—Dacarbazine—sarcoma	0.146	0.188	CbGbCtD
Dapagliflozin—CYP1A2—Dacarbazine—sarcoma	0.0653	0.0841	CbGbCtD
Dapagliflozin—CYP3A4—Thiotepa—sarcoma	0.0617	0.0795	CbGbCtD
Dapagliflozin—ABCB1—Dactinomycin—sarcoma	0.0495	0.0638	CbGbCtD
Dapagliflozin—ABCB1—Mitoxantrone—sarcoma	0.0443	0.0571	CbGbCtD
Dapagliflozin—CYP1A2—Etoposide—sarcoma	0.0319	0.0411	CbGbCtD
Dapagliflozin—ABCB1—Vincristine—sarcoma	0.0305	0.0393	CbGbCtD
Dapagliflozin—ABCB1—Etoposide—sarcoma	0.0279	0.036	CbGbCtD
Dapagliflozin—CYP3A4—Mitoxantrone—sarcoma	0.0265	0.0342	CbGbCtD
Dapagliflozin—UGT2B4—pericardium—sarcoma	0.0209	0.34	CbGeAlD
Dapagliflozin—ABCB1—Doxorubicin—sarcoma	0.0191	0.0245	CbGbCtD
Dapagliflozin—CYP3A4—Vincristine—sarcoma	0.0183	0.0235	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—sarcoma	0.018	0.0231	CbGbCtD
Dapagliflozin—CYP3A4—Etoposide—sarcoma	0.0167	0.0216	CbGbCtD
Dapagliflozin—CYP3A4—Doxorubicin—sarcoma	0.0114	0.0147	CbGbCtD
Dapagliflozin—SLC5A1—mammary gland—sarcoma	0.00648	0.105	CbGeAlD
Dapagliflozin—Hyperphosphataemia—Mitoxantrone—sarcoma	0.00466	0.0288	CcSEcCtD
Dapagliflozin—Balanitis—Epirubicin—sarcoma	0.00452	0.0279	CcSEcCtD
Dapagliflozin—Balanitis—Doxorubicin—sarcoma	0.00419	0.0258	CcSEcCtD
Dapagliflozin—SLC5A11—tendon—sarcoma	0.00413	0.0672	CbGeAlD
Dapagliflozin—SLC5A1—cardiac atrium—sarcoma	0.003	0.0488	CbGeAlD
Dapagliflozin—SLC5A2—testis—sarcoma	0.00285	0.0465	CbGeAlD
Dapagliflozin—UGT2B4—cardiac atrium—sarcoma	0.00276	0.045	CbGeAlD
Dapagliflozin—Serum creatinine increased—Mitoxantrone—sarcoma	0.00259	0.016	CcSEcCtD
Dapagliflozin—Hyperphosphataemia—Epirubicin—sarcoma	0.00217	0.0134	CcSEcCtD
Dapagliflozin—SLC5A1—testis—sarcoma	0.00216	0.0352	CbGeAlD
Dapagliflozin—Neoplasm malignant—Thiotepa—sarcoma	0.00216	0.0133	CcSEcCtD
Dapagliflozin—Extravasation—Thiotepa—sarcoma	0.00211	0.013	CcSEcCtD
Dapagliflozin—Extravasation—Dactinomycin—sarcoma	0.0021	0.0129	CcSEcCtD
Dapagliflozin—Fungal infection—Mitoxantrone—sarcoma	0.00206	0.0127	CcSEcCtD
Dapagliflozin—Hyperphosphataemia—Doxorubicin—sarcoma	0.00201	0.0124	CcSEcCtD
Dapagliflozin—UGT2B4—liver—sarcoma	0.00188	0.0307	CbGeAlD
Dapagliflozin—Extravasation—Vincristine—sarcoma	0.00187	0.0116	CcSEcCtD
Dapagliflozin—Extravasation—Mitoxantrone—sarcoma	0.00183	0.0113	CcSEcCtD
Dapagliflozin—Blood urea increased—Thiotepa—sarcoma	0.00174	0.0107	CcSEcCtD
Dapagliflozin—Phlebitis—Dactinomycin—sarcoma	0.00154	0.00951	CcSEcCtD
Dapagliflozin—Extravasation—Etoposide—sarcoma	0.00152	0.00936	CcSEcCtD
Dapagliflozin—CYP2A6—seminal vesicle—sarcoma	0.00151	0.0246	CbGeAlD
Dapagliflozin—Blood urea increased—Mitoxantrone—sarcoma	0.0015	0.00927	CcSEcCtD
Dapagliflozin—Urine output increased—Vincristine—sarcoma	0.00148	0.00912	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Epirubicin—sarcoma	0.00141	0.00871	CcSEcCtD
Dapagliflozin—Venous thrombosis—Epirubicin—sarcoma	0.00138	0.00849	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Epirubicin—sarcoma	0.00136	0.00838	CcSEcCtD
Dapagliflozin—Polyuria—Vincristine—sarcoma	0.00135	0.00834	CcSEcCtD
Dapagliflozin—Phlebitis—Mitoxantrone—sarcoma	0.00134	0.00828	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Doxorubicin—sarcoma	0.00131	0.00806	CcSEcCtD
Dapagliflozin—UGT1A9—liver—sarcoma	0.00129	0.021	CbGeAlD
Dapagliflozin—Venous thrombosis—Doxorubicin—sarcoma	0.00127	0.00785	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Doxorubicin—sarcoma	0.00126	0.00775	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Thiotepa—sarcoma	0.00125	0.00774	CcSEcCtD
Dapagliflozin—Dehydration—Thiotepa—sarcoma	0.00124	0.00768	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Epirubicin—sarcoma	0.00121	0.00745	CcSEcCtD
Dapagliflozin—Hyponatraemia—Vincristine—sarcoma	0.00119	0.00735	CcSEcCtD
Dapagliflozin—Pain in extremity—Vincristine—sarcoma	0.00119	0.00732	CcSEcCtD
Dapagliflozin—CYP2C9—mammary gland—sarcoma	0.00117	0.0191	CbGeAlD
Dapagliflozin—Hyponatraemia—Mitoxantrone—sarcoma	0.00116	0.00716	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Doxorubicin—sarcoma	0.00112	0.00689	CcSEcCtD
Dapagliflozin—Phlebitis—Etoposide—sarcoma	0.00112	0.00688	CcSEcCtD
Dapagliflozin—Dehydration—Vincristine—sarcoma	0.0011	0.00681	CcSEcCtD
Dapagliflozin—UGT2B7—testis—sarcoma	0.0011	0.0179	CbGeAlD
Dapagliflozin—Blood creatinine increased—Mitoxantrone—sarcoma	0.00108	0.00668	CcSEcCtD
Dapagliflozin—Dysuria—Thiotepa—sarcoma	0.00108	0.00667	CcSEcCtD
Dapagliflozin—Dehydration—Mitoxantrone—sarcoma	0.00108	0.00663	CcSEcCtD
Dapagliflozin—Lung disorder—Epirubicin—sarcoma	0.00105	0.00647	CcSEcCtD
Dapagliflozin—UGT2B7—liver—sarcoma	0.00104	0.0169	CbGeAlD
Dapagliflozin—Infestation—Thiotepa—sarcoma	0.00103	0.00636	CcSEcCtD
Dapagliflozin—Infestation NOS—Thiotepa—sarcoma	0.00103	0.00636	CcSEcCtD
Dapagliflozin—Renal failure—Thiotepa—sarcoma	0.00101	0.00625	CcSEcCtD
Dapagliflozin—Lung disorder—Doxorubicin—sarcoma	0.000971	0.00599	CcSEcCtD
Dapagliflozin—Fungal infection—Epirubicin—sarcoma	0.000962	0.00593	CcSEcCtD
Dapagliflozin—Dysuria—Vincristine—sarcoma	0.000959	0.00592	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Thiotepa—sarcoma	0.000915	0.00564	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Thiotepa—sarcoma	0.00091	0.00561	CcSEcCtD
Dapagliflozin—Urethral disorder—Thiotepa—sarcoma	0.000908	0.0056	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Vincristine—sarcoma	0.000902	0.00556	CcSEcCtD
Dapagliflozin—Myocardial infarction—Vincristine—sarcoma	0.000897	0.00553	CcSEcCtD
Dapagliflozin—Fungal infection—Doxorubicin—sarcoma	0.00089	0.00549	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Mitoxantrone—sarcoma	0.000878	0.00542	CcSEcCtD
Dapagliflozin—Renal failure—Mitoxantrone—sarcoma	0.000876	0.0054	CcSEcCtD
Dapagliflozin—Myocardial infarction—Mitoxantrone—sarcoma	0.000873	0.00539	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Epirubicin—sarcoma	0.00087	0.00536	CcSEcCtD
Dapagliflozin—Urinary tract infection—Mitoxantrone—sarcoma	0.000866	0.00534	CcSEcCtD
Dapagliflozin—Extravasation—Epirubicin—sarcoma	0.000851	0.00525	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Vincristine—sarcoma	0.000811	0.005	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Vincristine—sarcoma	0.000807	0.00498	CcSEcCtD
Dapagliflozin—Malnutrition—Thiotepa—sarcoma	0.000806	0.00497	CcSEcCtD
Dapagliflozin—Urethral disorder—Vincristine—sarcoma	0.000805	0.00497	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—sarcoma	0.000805	0.00496	CcSEcCtD
Dapagliflozin—Nocturia—Epirubicin—sarcoma	0.0008	0.00494	CcSEcCtD
Dapagliflozin—Extravasation—Doxorubicin—sarcoma	0.000787	0.00486	CcSEcCtD
Dapagliflozin—Back pain—Thiotepa—sarcoma	0.00078	0.00481	CcSEcCtD
Dapagliflozin—CYP1A2—hematopoietic system—sarcoma	0.000753	0.0123	CbGeAlD
Dapagliflozin—CYP1A1—hematopoietic system—sarcoma	0.000743	0.0121	CbGeAlD
Dapagliflozin—CYP2A6—liver—sarcoma	0.000743	0.0121	CbGeAlD
Dapagliflozin—Infestation—Etoposide—sarcoma	0.000741	0.00457	CcSEcCtD
Dapagliflozin—Infestation NOS—Etoposide—sarcoma	0.000741	0.00457	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—sarcoma	0.000741	0.00457	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Etoposide—sarcoma	0.00073	0.00451	CcSEcCtD
Dapagliflozin—Renal failure—Etoposide—sarcoma	0.000728	0.00449	CcSEcCtD
Dapagliflozin—Myocardial infarction—Etoposide—sarcoma	0.000726	0.00448	CcSEcCtD
Dapagliflozin—CYP2C9—hematopoietic system—sarcoma	0.000715	0.0117	CbGeAlD
Dapagliflozin—Vaginal infection—Epirubicin—sarcoma	0.000701	0.00432	CcSEcCtD
Dapagliflozin—Blood urea increased—Epirubicin—sarcoma	0.000701	0.00432	CcSEcCtD
Dapagliflozin—Hypertension—Thiotepa—sarcoma	0.000696	0.00429	CcSEcCtD
Dapagliflozin—Back pain—Vincristine—sarcoma	0.000691	0.00427	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000682	0.0042	CcSEcCtD
Dapagliflozin—Back pain—Mitoxantrone—sarcoma	0.000673	0.00415	CcSEcCtD
Dapagliflozin—Discomfort—Dactinomycin—sarcoma	0.000673	0.00415	CcSEcCtD
Dapagliflozin—Neoplasm—Epirubicin—sarcoma	0.000671	0.00414	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Etoposide—sarcoma	0.000657	0.00405	CcSEcCtD
Dapagliflozin—Infection—Thiotepa—sarcoma	0.000654	0.00403	CcSEcCtD
Dapagliflozin—Oedema—Dactinomycin—sarcoma	0.000653	0.00403	CcSEcCtD
Dapagliflozin—Urethral disorder—Etoposide—sarcoma	0.000652	0.00402	CcSEcCtD
Dapagliflozin—Infection—Dactinomycin—sarcoma	0.000649	0.004	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—sarcoma	0.000649	0.004	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—sarcoma	0.000649	0.004	CcSEcCtD
Dapagliflozin—CYP1A1—skin of body—sarcoma	0.000646	0.0105	CbGeAlD
Dapagliflozin—Skin disorder—Thiotepa—sarcoma	0.000639	0.00394	CcSEcCtD
Dapagliflozin—Phlebitis—Epirubicin—sarcoma	0.000626	0.00386	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—sarcoma	0.000621	0.00383	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Epirubicin—sarcoma	0.00062	0.00382	CcSEcCtD
Dapagliflozin—Hypertension—Vincristine—sarcoma	0.000617	0.00381	CcSEcCtD
Dapagliflozin—Hypertension—Mitoxantrone—sarcoma	0.000601	0.00371	CcSEcCtD
Dapagliflozin—Discomfort—Mitoxantrone—sarcoma	0.000586	0.00361	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Vincristine—sarcoma	0.000583	0.0036	CcSEcCtD
Dapagliflozin—Oedema—Vincristine—sarcoma	0.000583	0.0036	CcSEcCtD
Dapagliflozin—Infection—Vincristine—sarcoma	0.00058	0.00358	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—sarcoma	0.000579	0.00357	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Doxorubicin—sarcoma	0.000573	0.00354	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Mitoxantrone—sarcoma	0.000568	0.0035	CcSEcCtD
Dapagliflozin—Oedema—Mitoxantrone—sarcoma	0.000568	0.0035	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Thiotepa—sarcoma	0.000568	0.0035	CcSEcCtD
Dapagliflozin—Infection—Mitoxantrone—sarcoma	0.000564	0.00348	CcSEcCtD
Dapagliflozin—CYP1A1—cardiac atrium—sarcoma	0.000564	0.00919	CbGeAlD
Dapagliflozin—Hyperhidrosis—Vincristine—sarcoma	0.000564	0.00348	CcSEcCtD
Dapagliflozin—Constipation—Thiotepa—sarcoma	0.000563	0.00347	CcSEcCtD
Dapagliflozin—CYP1A1—uterus—sarcoma	0.000561	0.00915	CbGeAlD
Dapagliflozin—Back pain—Etoposide—sarcoma	0.00056	0.00346	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Epirubicin—sarcoma	0.000552	0.00341	CcSEcCtD
Dapagliflozin—Skin disorder—Mitoxantrone—sarcoma	0.000552	0.0034	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—sarcoma	0.00055	0.00339	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Mitoxantrone—sarcoma	0.000549	0.00339	CcSEcCtD
Dapagliflozin—CYP3A4—hematopoietic system—sarcoma	0.000545	0.00888	CbGeAlD
Dapagliflozin—Hypotension—Vincristine—sarcoma	0.000545	0.00336	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—sarcoma	0.000541	0.00334	CcSEcCtD
Dapagliflozin—Pain in extremity—Epirubicin—sarcoma	0.000539	0.00332	CcSEcCtD
Dapagliflozin—CYP2D6—hematopoietic system—sarcoma	0.000537	0.00874	CbGeAlD
Dapagliflozin—Hypotension—Mitoxantrone—sarcoma	0.000531	0.00327	CcSEcCtD
Dapagliflozin—Urticaria—Thiotepa—sarcoma	0.000523	0.00322	CcSEcCtD
Dapagliflozin—Body temperature increased—Thiotepa—sarcoma	0.00052	0.00321	CcSEcCtD
Dapagliflozin—Body temperature increased—Dactinomycin—sarcoma	0.000516	0.00318	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—sarcoma	0.000511	0.00315	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—sarcoma	0.000509	0.00314	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Epirubicin—sarcoma	0.000505	0.00311	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Vincristine—sarcoma	0.000504	0.00311	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—sarcoma	0.000501	0.00309	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—sarcoma	0.000501	0.00309	CcSEcCtD
Dapagliflozin—Hypertension—Etoposide—sarcoma	0.0005	0.00308	CcSEcCtD
Dapagliflozin—Constipation—Vincristine—sarcoma	0.000499	0.00308	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—sarcoma	0.000499	0.00308	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—sarcoma	0.000492	0.00304	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00049	0.00302	CcSEcCtD
Dapagliflozin—Discomfort—Etoposide—sarcoma	0.000487	0.003	CcSEcCtD
Dapagliflozin—Constipation—Mitoxantrone—sarcoma	0.000486	0.003	CcSEcCtD
Dapagliflozin—Hypersensitivity—Thiotepa—sarcoma	0.000485	0.00299	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—sarcoma	0.000482	0.00297	CcSEcCtD
Dapagliflozin—Hypersensitivity—Dactinomycin—sarcoma	0.000481	0.00297	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Etoposide—sarcoma	0.000473	0.00292	CcSEcCtD
Dapagliflozin—Infection—Etoposide—sarcoma	0.00047	0.0029	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—sarcoma	0.000467	0.00288	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—sarcoma	0.000466	0.00287	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—sarcoma	0.000464	0.00286	CcSEcCtD
Dapagliflozin—Body temperature increased—Vincristine—sarcoma	0.000461	0.00284	CcSEcCtD
Dapagliflozin—Skin disorder—Etoposide—sarcoma	0.000459	0.00283	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Etoposide—sarcoma	0.000457	0.00282	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—sarcoma	0.000455	0.00281	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—sarcoma	0.000454	0.0028	CcSEcCtD
Dapagliflozin—Urticaria—Mitoxantrone—sarcoma	0.000451	0.00278	CcSEcCtD
Dapagliflozin—ABCB1—myometrium—sarcoma	0.00045	0.00732	CbGeAlD
Dapagliflozin—Body temperature increased—Mitoxantrone—sarcoma	0.000449	0.00277	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—sarcoma	0.000446	0.00275	CcSEcCtD
Dapagliflozin—Hypotension—Etoposide—sarcoma	0.000442	0.00272	CcSEcCtD
Dapagliflozin—Dysuria—Epirubicin—sarcoma	0.000436	0.00269	CcSEcCtD
Dapagliflozin—Dizziness—Thiotepa—sarcoma	0.000435	0.00268	CcSEcCtD
Dapagliflozin—ABCB1—embryo—sarcoma	0.000432	0.00704	CbGeAlD
Dapagliflozin—Influenza—Doxorubicin—sarcoma	0.000431	0.00266	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—sarcoma	0.00043	0.00265	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vincristine—sarcoma	0.00043	0.00265	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—sarcoma	0.00042	0.00259	CcSEcCtD
Dapagliflozin—Hypersensitivity—Mitoxantrone—sarcoma	0.000419	0.00258	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—sarcoma	0.000415	0.00256	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—sarcoma	0.000415	0.00256	CcSEcCtD
Dapagliflozin—Rash—Thiotepa—sarcoma	0.000415	0.00256	CcSEcCtD
Dapagliflozin—Dermatitis—Thiotepa—sarcoma	0.000414	0.00256	CcSEcCtD
Dapagliflozin—Headache—Thiotepa—sarcoma	0.000412	0.00254	CcSEcCtD
Dapagliflozin—Rash—Dactinomycin—sarcoma	0.000412	0.00254	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—sarcoma	0.000408	0.00252	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Etoposide—sarcoma	0.000408	0.00252	CcSEcCtD
Dapagliflozin—ABCB1—seminal vesicle—sarcoma	0.000406	0.00662	CbGeAlD
Dapagliflozin—Constipation—Etoposide—sarcoma	0.000404	0.00249	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—sarcoma	0.000404	0.00249	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—sarcoma	0.000403	0.00249	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—sarcoma	0.000398	0.00246	CcSEcCtD
Dapagliflozin—Nausea—Thiotepa—sarcoma	0.000391	0.00241	CcSEcCtD
Dapagliflozin—CYP1A2—liver—sarcoma	0.00039	0.00636	CbGeAlD
Dapagliflozin—Nausea—Dactinomycin—sarcoma	0.000388	0.00239	CcSEcCtD
Dapagliflozin—ABCB1—hematopoietic system—sarcoma	0.000386	0.00629	CbGeAlD
Dapagliflozin—Dizziness—Vincristine—sarcoma	0.000386	0.00238	CcSEcCtD
Dapagliflozin—CYP1A1—liver—sarcoma	0.000385	0.00627	CbGeAlD
Dapagliflozin—Infestation NOS—Doxorubicin—sarcoma	0.000384	0.00237	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—sarcoma	0.000384	0.00237	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—sarcoma	0.000378	0.00233	CcSEcCtD
Dapagliflozin—Urticaria—Etoposide—sarcoma	0.000375	0.00232	CcSEcCtD
Dapagliflozin—Body temperature increased—Etoposide—sarcoma	0.000374	0.0023	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—sarcoma	0.000374	0.0023	CcSEcCtD
Dapagliflozin—CYP2C9—liver—sarcoma	0.000371	0.00604	CbGeAlD
Dapagliflozin—Urinary tract disorder—Epirubicin—sarcoma	0.000368	0.00227	CcSEcCtD
Dapagliflozin—Rash—Vincristine—sarcoma	0.000368	0.00227	CcSEcCtD
Dapagliflozin—Dermatitis—Vincristine—sarcoma	0.000368	0.00227	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—sarcoma	0.000366	0.00226	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—sarcoma	0.000366	0.00225	CcSEcCtD
Dapagliflozin—Headache—Vincristine—sarcoma	0.000365	0.00225	CcSEcCtD
Dapagliflozin—Rash—Mitoxantrone—sarcoma	0.000358	0.00221	CcSEcCtD
Dapagliflozin—Dermatitis—Mitoxantrone—sarcoma	0.000358	0.00221	CcSEcCtD
Dapagliflozin—Headache—Mitoxantrone—sarcoma	0.000356	0.0022	CcSEcCtD
Dapagliflozin—Hypersensitivity—Etoposide—sarcoma	0.000348	0.00215	CcSEcCtD
Dapagliflozin—Nausea—Vincristine—sarcoma	0.000347	0.00214	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—sarcoma	0.000341	0.0021	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—sarcoma	0.000339	0.00209	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—sarcoma	0.000338	0.00209	CcSEcCtD
Dapagliflozin—Nausea—Mitoxantrone—sarcoma	0.000337	0.00208	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—sarcoma	0.000325	0.002	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—sarcoma	0.000314	0.00194	CcSEcCtD
Dapagliflozin—Dizziness—Etoposide—sarcoma	0.000313	0.00193	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—sarcoma	0.0003	0.00185	CcSEcCtD
Dapagliflozin—Rash—Etoposide—sarcoma	0.000298	0.00184	CcSEcCtD
Dapagliflozin—Dermatitis—Etoposide—sarcoma	0.000298	0.00184	CcSEcCtD
Dapagliflozin—Headache—Etoposide—sarcoma	0.000296	0.00183	CcSEcCtD
Dapagliflozin—CYP1A1—lymph node—sarcoma	0.000295	0.00481	CbGeAlD
Dapagliflozin—CYP2D6—testis—sarcoma	0.000294	0.00479	CbGeAlD
Dapagliflozin—ABCB1—uterus—sarcoma	0.000292	0.00475	CbGeAlD
Dapagliflozin—Back pain—Doxorubicin—sarcoma	0.000291	0.00179	CcSEcCtD
Dapagliflozin—CYP3A4—liver—sarcoma	0.000283	0.0046	CbGeAlD
Dapagliflozin—Nausea—Etoposide—sarcoma	0.000281	0.00173	CcSEcCtD
Dapagliflozin—Hypertension—Epirubicin—sarcoma	0.00028	0.00173	CcSEcCtD
Dapagliflozin—CYP2D6—liver—sarcoma	0.000278	0.00453	CbGeAlD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000274	0.00169	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—sarcoma	0.000273	0.00168	CcSEcCtD
Dapagliflozin—ABCB1—lymphoid tissue—sarcoma	0.000272	0.00443	CbGeAlD
Dapagliflozin—Anaphylactic shock—Epirubicin—sarcoma	0.000265	0.00163	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—sarcoma	0.000265	0.00163	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—sarcoma	0.000263	0.00162	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—sarcoma	0.000259	0.0016	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—sarcoma	0.000257	0.00159	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—sarcoma	0.000256	0.00158	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000254	0.00157	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—sarcoma	0.000253	0.00156	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—sarcoma	0.000248	0.00153	CcSEcCtD
Dapagliflozin—ABCB1—bone marrow—sarcoma	0.000247	0.00403	CbGeAlD
Dapagliflozin—Anaphylactic shock—Doxorubicin—sarcoma	0.000245	0.00151	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—sarcoma	0.000245	0.00151	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—sarcoma	0.000244	0.0015	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—sarcoma	0.000238	0.00147	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—sarcoma	0.000237	0.00146	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—sarcoma	0.000229	0.00141	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—sarcoma	0.000229	0.00141	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—sarcoma	0.000227	0.0014	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000212	0.00131	CcSEcCtD
Dapagliflozin—ABCB1—testis—sarcoma	0.000212	0.00345	CbGeAlD
Dapagliflozin—Urticaria—Epirubicin—sarcoma	0.00021	0.0013	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—sarcoma	0.00021	0.00129	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—sarcoma	0.000209	0.00129	CcSEcCtD
Dapagliflozin—ABCB1—liver—sarcoma	0.0002	0.00326	CbGeAlD
Dapagliflozin—Hypersensitivity—Epirubicin—sarcoma	0.000195	0.0012	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—sarcoma	0.000195	0.0012	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—sarcoma	0.000194	0.0012	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—sarcoma	0.000181	0.00111	CcSEcCtD
Dapagliflozin—Dizziness—Epirubicin—sarcoma	0.000175	0.00108	CcSEcCtD
Dapagliflozin—Rash—Epirubicin—sarcoma	0.000167	0.00103	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—sarcoma	0.000167	0.00103	CcSEcCtD
Dapagliflozin—Headache—Epirubicin—sarcoma	0.000166	0.00102	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—sarcoma	0.000162	0.001	CcSEcCtD
Dapagliflozin—Nausea—Epirubicin—sarcoma	0.000157	0.000971	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—sarcoma	0.000155	0.000953	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—sarcoma	0.000154	0.000952	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—sarcoma	0.000154	0.000947	CcSEcCtD
Dapagliflozin—ABCB1—lymph node—sarcoma	0.000153	0.0025	CbGeAlD
Dapagliflozin—Nausea—Doxorubicin—sarcoma	0.000146	0.000898	CcSEcCtD
